Aptuit Appoints New CEO - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aptuit Appoints New CEO



Untitled Document

Aptuit, a provider of outsourced services in the early development space, has appointed Jonathan Goldman, MD, as the company’s new CEO. Goldman joins the company after working at ICON Clinical Research.

Goldman was most recently executive vice president, global strategic and business development at ICON and a member of the senior leadership team. Previously, his roles at ICON included executive VP, operations, strategic programs and chief medical officer, ICON Medical Imaging.

Before joining ICON, Goldman served for seven years as the chief medical officer of POINT Biomedical, a US-based biopharmaceutical company that discovered and developed microsphere technologies and drugs. In addition, he has held academic positions at the University of California since 2000, most recently as associate clinical professor of medicine in the Division of Cardiology.

Source: Aptuit

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
25%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
36%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here